cjc-1295 ipamorelin clinical studies growth hormone secretagogues study secretagogue Peptide: Structure, Benefits, and Research Use Blog Sublingual CJC-1295 Ipamorelin / CJC-1295 (With DAC):

For example, a patient with chronic tendon pain may need imaging, physical therapy, load management, nutrition support, and a diagnosis before any peptide conversation makes sense

Features Joint therapy approved by the FDA for both intravenous and intra-articular use, allowing treatment tailored to the veterinarian's preference and the horse's individual needs Millions of doses sold 5 More than 25 years of treatment success Safe and effective, proven by multiple studies Reduces production of inflammatory mediators, joint inflammation and the resulting lameness for at least 45 days after being given once a week for three weeks 4 Benefits Safe and effective 90% of cases treated intravenously judged to have excellent to good overall clinical improvement 1 96% of horses treated intra-articularly were judged to have excellent to good overall clinical improvement 1 Improvement can be seen after one dose Breaks the cycle of inflammation and lameness associated with synovitis Stimulates endogenous hyaluronic acid production 2 Decreases the presence of inflammatory mediators 4 Easy to use I.V

Never use the same needle twice, as this can lead to infection or illness

Unwanted effects could be mild to severe, depending on the dosage

S2CID 7641257